

**Reagent needs for neotropical primates**

The Neotropical Primates in Biomedical Research Workshop ([http://www.ncrr.nih.gov/publications/comparative\\_medicine/summary\\_of\\_the\\_neotropical\\_primates\\_in\\_biomedical\\_research\\_workshop.asp#discussions](http://www.ncrr.nih.gov/publications/comparative_medicine/summary_of_the_neotropical_primates_in_biomedical_research_workshop.asp#discussions)), was sponsored by the Office of Research Infrastructure Programs, DPCPSI, OD, National Institutes of Health on September 22-23, 2010. In response to this workshop, the NHP Reagent Resource has tentatively identified reagents needed to better utilize these species as animal models of human diseases. This list will be used to guide new reagent development.

Comments (<http://www.nhpreagents.org/NHP/contactgeneral.aspx>) on proposed reagents, species or assigned priority are welcome.

Details:

☞ Antibodies for cell staining (flow cytometry or IHC)

	<i>Callithrix jacchus</i>	<i>Saguinus spp</i>	<i>Saimiri spp</i>	<i>Aotus spp</i>
<b>CD2</b>	AVAILABLE		AVAILABLE	
<b>CD3</b>	AVAILABLE	AVAILABLE	AVAILABLE	AVAILABLE
<b>CD4</b>	AVAILABLE	AVAILABLE	AVAILABLE	AVAILABLE
<b>CD8a</b>	AVAILABLE	AVAILABLE	AVAILABLE	AVAILABLE
<b>CD8b</b>	HIGH PRIORITY	MED PRIORITY	HIGH PRIORITY	MED PRIORITY
<b>CD11b</b>	AVAILABLE			
<b>CD13</b>		AVAILABLE		
<b>CD14</b>	HIGH PRIORITY	AVAILABLE	AVAILABLE	
<b>CD16</b>	AVAILABLE		AVAILABLE	
<b>CD18</b>	AVAILABLE	AVAILABLE	HIGH PRIORITY	MED PRIORITY
<b>CD20</b>	AVAILABLE	AVAILABLE	AVAILABLE	AVAILABLE
<b>CD21</b>			AVAILABLE	
<b>CD25</b>	AVAILABLE	AVAILABLE	AVAILABLE	
<b>CD27</b>	AVAILABLE			
<b>CD28</b>	AVAILABLE		AVAILABLE	
<b>CD29</b>			AVAILABLE	
<b>CD35</b>	AVAILABLE	AVAILABLE		
<b>CD40</b>	AVAILABLE			
<b>CD44</b>	AVAILABLE	AVAILABLE		
<b>CD45RA</b>	AVAILABLE	AVAILABLE	AVAILABLE	
<b>CD49d</b>	AVAILABLE			
<b>CD56</b>	AVAILABLE			
<b>CD64</b>			AVAILABLE	
<b>CD80</b>	AVAILABLE		AVAILABLE	
<b>CD83</b>			AVAILABLE	
<b>CD86</b>	AVAILABLE			
<b>CD95</b>	AVAILABLE	AVAILABLE	HIGH PRIORITY	
<b>CD138</b>		AVAILABLE		
<b>CD159a (NKG2a)</b>	AVAILABLE	MED PRIORITY	HIGH PRIORITY	MED PRIORITY
<b>CD314 (NKG2d)</b>	AVAILABLE			
<b>CD335 (NKp46)</b>	AVAILABLE			
<b>CD337(NKp30)</b>	AVAILABLE			

⇒ Antibodies against cytokines and chemokines

	<i>Callithrix jacchus</i>	<i>Saguinus spp</i>	<i>Saimiri spp</i>	<i>Aotus spp</i>
<b>Cytokine antibodies</b>				
IL-1				
IL-2				
IL-4				
IL-5				
IL-6				
IL-7				
IL-10				
IL-12				
IL-15				
IL-17				
IFN-[alpha]				
IFN-[gamma]				
GM-CSF				
sIL-6R				
TNF-[alpha]	AVAILABLE			
MIP-1[alpha]				
MIP-1[beta]				
<b>Chemokine antibodies</b>				
CD195 (CCR5)	AVAILABLE			
<b>Cytokine ELISA kits</b>				
IFN-gamma	AVAILABLE		AVAILABLE	AVAILABLE
IL-1b	AVAILABLE			
IL-13	AVAILABLE			
IL-17	AVAILABLE			
TNF-alpha	AVAILABLE			

⇒ Antibodies against Ig and reference Ig reagents

	<i>Callithrix jacchus</i>	<i>Saguinus spp</i>	<i>Saimiri spp</i>	<i>Aotus spp</i>
<b>Antibodies against Ig</b>				
IgG	HIGH PRIORITY	MED PRIORITY	HIGH PRIORITY	MED PRIORITY
IgA	HIGH PRIORITY	MED PRIORITY	HIGH PRIORITY	MED PRIORITY
IgM	HIGH PRIORITY			
IgD	HIGH PRIORITY			
IgE	HIGH PRIORITY			
IgG1	HIGH PRIORITY			
IgG2	HIGH PRIORITY			
IgG3	HIGH PRIORITY			
IgG4	HIGH PRIORITY			
<b>Reference reagents</b>				
IgG	EXISTS	MED PRIORITY	HIGH PRIORITY	MED PRIORITY
IgG isotypes	HIGH PRIORITY			
IgA	HIGH PRIORITY	MED PRIORITY	HIGH PRIORITY	MED PRIORITY
IgM	HIGH PRIORITY	MED PRIORITY	HIGH PRIORITY	MED PRIORITY

☞ Antibodies for in vivo administration (cell-depleting)

	<i>Callithrix jacchus</i>	<i>Saguinus spp</i>	<i>Saimiri spp</i>	<i>Aotus spp</i>
<b>Cell-depleting mAbs</b>				
<b>CD8</b>	HIGH PRIORITY		HIGH PRIORITY	
<b>CD20</b>	HIGH PRIORITY		HIGH PRIORITY	
<b>CD4</b>	HIGH PRIORITY		HIGH PRIORITY	